ArticleInterdisciplinary cardiovascular and thoracic surgery2025
Durability Testing With Calcification of Surgical Aortic Valves and Transcatheter Heart Valves: An In Vitro Study.
Article in Interdisciplinary cardiovascular and thoracic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesStructural valve deterioration, mainly caused by calcification, is the Achilles heel of the bioprosthetic heart valves. While clinical long-term experience of surgical aortic valve (SAV) bioprostheses exists, transcatheter heart valve (THV) requires further investigations into biological degeneration. Therefore, this in vitro study aimed to analyse the calcification pattern of different SAV and THV models under standardized conditions.
methodsSAVs (Perimount Magna Ease, Perimount, Mosaic Ultra and Hancock II) and THVs (Evolut PRO and SAPIEN XT) models were calcified with a calcification buffer (pH = 7.4 and CaCl2 = 1.5 mM) circulating at 37°C over 157.684 million cycles in a Hi-Cycle-tester to simulate 5 patient-years. Hydrodynamic performance (mean pressure gradient [MPG] and effective orifice area [EOA]) of the valves were compared in a pulse duplicator before and after calcification. The calcified group and one untreated prosthesis (control group) were analysed by macroscopic evaluation, tissue thickness measurement, calcium titration, scanning electron microscopy, and histological examination (n = 12).
resultsAfter durability testing, the MPG and EOA of all valves changed significantly, except for Evolut PRO. The valve leaflets of the calcified group presented hydroxyapatite crystals and a distinct calcification along regions with high mechanical stress-the commissures, nadirs, and ventricle side. Durability testing with calcification buffer resulted in significantly higher calcium content within all valve models' leaflets than in their control group. The THVs showed superiority vs surgical valves regarding the susceptibility to calcification, with a degree of calcification differing significantly depending on the valve model.
conclusionsThe Evolut PRO THV's functional performance was not significantly impaired after durability testing. Further clinical evaluation of this aspect is essential to confirm the susceptibility to calcification of bioprosthetic heart valves.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.